SE460907B - Humanmyelomcellinje, komposition innehaallande saadana celler, samt foerfarande foer cellinjens framstaellning - Google Patents
Humanmyelomcellinje, komposition innehaallande saadana celler, samt foerfarande foer cellinjens framstaellningInfo
- Publication number
- SE460907B SE460907B SE8106528A SE8106528A SE460907B SE 460907 B SE460907 B SE 460907B SE 8106528 A SE8106528 A SE 8106528A SE 8106528 A SE8106528 A SE 8106528A SE 460907 B SE460907 B SE 460907B
- Authority
- SE
- Sweden
- Prior art keywords
- cell line
- cell
- human
- cells
- hybrid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 239000000203 mixture Substances 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims description 88
- 210000004698 lymphocyte Anatomy 0.000 claims description 37
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 33
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 32
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 11
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 11
- 201000005505 Measles Diseases 0.000 claims description 8
- 241000712079 Measles morbillivirus Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 210000004754 hybrid cell Anatomy 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 210000004989 spleen cell Anatomy 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 description 18
- 239000002609 medium Substances 0.000 description 13
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 7
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- MEOVPKDOYAIVHZ-UHFFFAOYSA-N 2-chloro-1-(1-methylpyrrol-2-yl)ethanol Chemical compound CN1C=CC=C1C(O)CCl MEOVPKDOYAIVHZ-UHFFFAOYSA-N 0.000 description 2
- KYHPMCZXXRPOKS-ZJWYQBPBSA-N 3,7-dihydropurin-6-one;2-hydrazinyl-1h-pteridin-4-one;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KYHPMCZXXRPOKS-ZJWYQBPBSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20483280A | 1980-11-07 | 1980-11-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8106528L SE8106528L (sv) | 1982-05-08 |
| SE460907B true SE460907B (sv) | 1989-12-04 |
Family
ID=22759633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8106528A SE460907B (sv) | 1980-11-07 | 1981-11-04 | Humanmyelomcellinje, komposition innehaallande saadana celler, samt foerfarande foer cellinjens framstaellning |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JPS57126424A (enExample) |
| AT (1) | AT380898B (enExample) |
| AU (1) | AU548738B2 (enExample) |
| BE (1) | BE891003A (enExample) |
| CA (1) | CA1198066A (enExample) |
| CH (1) | CH658070A5 (enExample) |
| DE (1) | DE3144181A1 (enExample) |
| FR (1) | FR2493865A1 (enExample) |
| GB (1) | GB2086937B (enExample) |
| IT (1) | IT1140050B (enExample) |
| NZ (1) | NZ198851A (enExample) |
| SE (1) | SE460907B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1200484A (en) * | 1981-12-08 | 1986-02-11 | Medical University Of South Carolina | Human monoclonal antibodies and lymphokines |
| CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
| JPS58201994A (ja) * | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| US4618577A (en) * | 1983-02-09 | 1986-10-21 | The Regents Of The University Of California | Human-human hybridoma, CLNH5 |
| JPS58205773A (ja) * | 1982-05-27 | 1983-11-30 | Canon Inc | インクジエツトプリンタ |
| DE3379055D1 (en) * | 1982-06-09 | 1989-03-02 | Asahi Chemical Ind | Method for producing human antibody |
| US4744982A (en) * | 1982-08-24 | 1988-05-17 | Hunter Kenneth W | Human monoclonal antibody reactive with polyribosylribitol phosphate |
| US4689299A (en) * | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| CA1262238C (en) | 1982-09-30 | 1989-10-10 | HUMAN MONOCLONAL ANTIBODIES AGAINST BACTERIAL TOXINS | |
| CA1214123A (en) * | 1983-01-20 | 1986-11-18 | Masashi Matsui | Cell lines for use in the preparation of hybridoma cells |
| US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
| US4693966A (en) * | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
| CA1218947A (en) * | 1983-04-06 | 1987-03-10 | Pearl M.J. Chen | Human hybrid cell lines |
| JPS6133125A (ja) * | 1984-07-25 | 1986-02-17 | Morinaga & Co Ltd | ヒト単クロ−ン性抗肺ガン細胞抗体 |
| JPS61104796A (ja) * | 1984-10-26 | 1986-05-23 | Chemo Sero Therapeut Res Inst | モノクロ−ナル抗体の製造方法 |
| US4677070A (en) * | 1985-04-26 | 1987-06-30 | Cetus Corporation | Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use |
| EP0239102A3 (en) * | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| AU3432389A (en) * | 1988-04-07 | 1989-11-03 | Farmitalia Carlo Erba S.R.L. | Human monoclonal antibodies against rabies virus |
| CA2002067A1 (en) | 1988-11-09 | 1990-05-09 | Tamotsu Fukuda | Parent cell line for producing human hybridomas |
| US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
-
1981
- 1981-11-03 NZ NZ198851A patent/NZ198851A/en unknown
- 1981-11-04 SE SE8106528A patent/SE460907B/sv not_active Application Discontinuation
- 1981-11-04 CH CH7057/81A patent/CH658070A5/fr not_active IP Right Cessation
- 1981-11-04 IT IT24862/81A patent/IT1140050B/it active
- 1981-11-05 AT AT0476381A patent/AT380898B/de not_active IP Right Cessation
- 1981-11-05 BE BE0/206450A patent/BE891003A/fr not_active IP Right Cessation
- 1981-11-05 GB GB8133387A patent/GB2086937B/en not_active Expired
- 1981-11-06 DE DE19813144181 patent/DE3144181A1/de not_active Withdrawn
- 1981-11-06 CA CA000389655A patent/CA1198066A/en not_active Expired
- 1981-11-06 JP JP56178255A patent/JPS57126424A/ja active Pending
- 1981-11-06 AU AU77167/81A patent/AU548738B2/en not_active Ceased
- 1981-11-06 FR FR8120798A patent/FR2493865A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2493865B1 (enExample) | 1984-12-14 |
| GB2086937B (en) | 1985-05-30 |
| JPS57126424A (en) | 1982-08-06 |
| FR2493865A1 (fr) | 1982-05-14 |
| BE891003A (fr) | 1982-03-01 |
| IT8124862A0 (it) | 1981-11-04 |
| NZ198851A (en) | 1984-07-31 |
| CA1198066A (en) | 1985-12-17 |
| AT380898B (de) | 1986-07-25 |
| AU548738B2 (en) | 1986-01-02 |
| ATA476381A (de) | 1985-12-15 |
| IT1140050B (it) | 1986-09-24 |
| SE8106528L (sv) | 1982-05-08 |
| DE3144181A1 (de) | 1982-09-09 |
| CH658070A5 (fr) | 1986-10-15 |
| GB2086937A (en) | 1982-05-19 |
| AU7716781A (en) | 1982-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4608337A (en) | Human hybridomas and the production of human monoclonal antibodies by human hybridomas | |
| SE460907B (sv) | Humanmyelomcellinje, komposition innehaallande saadana celler, samt foerfarande foer cellinjens framstaellning | |
| Taniguchi et al. | Antigen-specific suppressive factor produced by a transplantable IJ bearing T-cell hybridoma | |
| EP0488470B1 (en) | Method for the production of antibodies | |
| US4594325A (en) | High fusion frequency fusible lymphoblastoid cell line | |
| FI83538C (fi) | Foerfarande foer produktion av en hybridomcellinje. | |
| JPS5845407B2 (ja) | 悪性腫瘍抗体の製造方法 | |
| Bartal et al. | Methods of hybridoma formation | |
| JPH0753110B2 (ja) | 細胞産生物を取得する方法 | |
| Dorfman | The optimal technological approach to the development of human hybridomas | |
| Sompayrac et al. | Stabilization of the 53,000-dalton nonviral tumor antigen is not required for transformation by simian virus 40 | |
| US8173425B2 (en) | Fusion partner cells | |
| Howes et al. | Mouse hybrid cell lines produce antibodies to herpes simplex virus type 1 | |
| US4618585A (en) | Hybridoma cell lines producing monoclonal antibodies directed against cervical cancer cells | |
| Treves et al. | Establishment of cell lines from somatic cell hybrids between human monocytes and mouse myeloma cells. | |
| Yoshida et al. | Ig gene rearrangement and expression in the progeny of B‐cell progenitors in the course of clonal expansion in bone marrow cultures. | |
| Witte et al. | Thy-1 antigen is present on B and T lymphocytes of the Syrian hamster. | |
| RU2092554C1 (ru) | Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к вирусу болезни ауески штамм унииэв 18 в | |
| WO1989000607A1 (en) | Preparation of human monoclonal antibodies of selected specificity and isotypes | |
| JPH0751600B2 (ja) | モノクローナル抗体およびそれを用いた識別方法 | |
| RU2012594C1 (ru) | Штамм гибридных культивируемых клеток животных mus musculus l - продуцент моноклональных антител к 146s-компоненту вируса ящура азия-1 | |
| RU2031117C1 (ru) | Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу простого герпеса i типа | |
| JP3395817B2 (ja) | マイコプラズマ・ガリセプティカムに対するモノクローナル抗体を産生するハイブリドーマ、モノクローナル抗体、およびその利用 | |
| RU2741095C2 (ru) | Способ получения клеточных линий, стабильно продуцирующих человеческие моноклональные антитела класса igg | |
| EP0362755A2 (en) | Human cytotoxic t-cell clone and antibody thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAV | Patent application has lapsed |
Ref document number: 8106528-6 Effective date: 19900810 |